Longeveron/LGVN

$0.54

1.12%
-
1D1W1MYTD1YMAX

About Longeveron

Longeveron Inc. is a clinical-stage biotechnology company, which is developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, such as aging related frailty, Alzheimer's disease (AD), acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.

Ticker

LGVN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Wa'el Hashad

Employees

19

Headquarters

Miami, United States

Longeveron Metrics

BasicAdvanced
$13.42M
Market cap
-
P/E ratio
-$0.94
EPS
-
Beta
-
Dividend rate

What the Analysts think about Longeveron

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 3 analysts.
1,646.3% upside
High $14.30
Low $6.00
$0.54
Current price
$9.43
Average price target

Longeveron Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-5,100% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$100K
-50%
Net income
$-5.1M
-8.93%
Profit margin
-5,100%
82.14%

Longeveron Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 19.05%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.22
-$0.27
-$0.28
-$0.25
-
Expected
-$0.21
-$0.25
-$0.23
-$0.21
-$0.17
Surprise
4.76%
9.46%
24.44%
19.05%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Longeveron stock

Buy or sell Longeveron stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing